[Skip to Navigation]
Comment & Response
August 2018

Considering Pharmaceutical Rebates

Author Affiliations
  • 1Grant Family Medicine, Ohio Health, Columbus
  • 2Department of Family Medicine, University of Michigan, Ann Arbor
JAMA Intern Med. 2018;178(8):1139-1140. doi:10.1001/jamainternmed.2018.3044

To the Editor We read the recent article by Warraich and colleagues1 with much interest. The authors concluded that despite the availability of generic atorvastatin, payers continue to pay substantial excess expenditures for Lipitor (Pfizer). Unfortunately, proprietary pharmaceutical industry rebates make it difficult to assess the validity of this conclusion.

Add or change institution